Bicara Therapeutics Inc.
BCAX
$22.38
-$0.54-2.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -78.39% | -107.83% | -60.64% | -194.58% | -68.46% |
| Total Depreciation and Amortization | 186.67% | 60.00% | 46.15% | 46.15% | 7.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.63% | 85.56% | 235.42% | 196.12% | 100.90% |
| Change in Net Operating Assets | 170.38% | 270.33% | -163.76% | 255.33% | -507.44% |
| Cash from Operations | 20.46% | -69.81% | -98.28% | -92.68% | -273.72% |
| Capital Expenditure | -495.00% | -425.00% | -- | -- | 90.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -205,730.00% | -2,951,412.50% | -- | -- | 90.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -99.87% | -89.85% | 235.77% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,303.08% | -99.87% | -81.61% | 235.77% | -100.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -141.53% | -183.60% | -108.80% | -92.09% | -116.67% |